Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Mol Neurobiol ; 58(6): 2704-2723, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33492644

ABSTRACT

Huntington's disease (HD) is a progressive neurodegenerative disorder caused by an expansion of polyglutamine stretch (polyQ) at the N-terminus of huntingtin (Htt) protein. The abnormally expanded polyQ stretch of mutant Htt makes it prone to aggregate, leading to neuropathology. HAP40 is a 40-kDa huntingtin-associated protein with undefined functions. HAP40 protein has been shown to increase in HD patients and HD mouse model cells. However, recent proteomic analysis provides new evidence that HAP40 protein is decreased in the striatum of HD knockin model mice. In this study, we developed HAP40-specific antibody and showed that both HAP40 mRNA and its encoded protein were reduced in HD striatal neuronal STHDHQ111/Q111 cells. Depletion of endogenous HAP40 led to cytotoxicity that was linked to increased accumulation of aggregated and soluble forms of mutant Htt, which recapitulates HD pathology. Moreover, we found that HAP40 depletion reduced the proteasomal chymotrypsin-like activity and increased the autophagic flux. Importantly, inhibition of p38 MAPK pathway by PD169316 increased chymotrypsin-like activity and reduced accumulation of aggregated and soluble forms of mutant Htt in HAP40-depleted cells to alleviate HAP40-depletion induced cytotoxicity. Taken together, our results suggest that modulation of p38 MAPK-mediated proteasomal peptidase activity may provide a new therapeutic target to restore proteostasis in neurodegenerative diseases.


Subject(s)
Huntington Disease/enzymology , Huntington Disease/pathology , Intracellular Signaling Peptides and Proteins/deficiency , Proteasome Endopeptidase Complex/metabolism , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , Animals , Autophagy/drug effects , Cell Line , Chymotrypsin/metabolism , Corpus Striatum/metabolism , Corpus Striatum/pathology , Disease Models, Animal , Green Fluorescent Proteins/metabolism , Huntingtin Protein/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Mice , Mutant Proteins/metabolism , Protein Aggregates/drug effects , Protein Kinase Inhibitors/pharmacology , Protein Subunits/metabolism , Solubility , Ubiquitin/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
2.
Int J Mol Sci ; 21(21)2020 Nov 06.
Article in English | MEDLINE | ID: mdl-33171990

ABSTRACT

We investigated the therapeutic potential and mechanism of chitosan oligosaccharides (COS) for experimental autoimmune uveoretinitis (EAU) in mice. EAU was induced in C57/BL6 mice by injection of human interphotoreceptor retinoid-binding protein (IRBP) peptides. At the same time, a high or low dose (20 or 10 mg/kg) of COS or phosphate-buffered saline (PBS) was given to mice daily after EAU induction. We found that mouse EAU is ameliorated by the high-dose COS treatment when compared with PBS treatment. In the retinas of high-dose COS-treated mice, the nuclear translocation of NF-κB subunit (p65) was suppressed, and the expression of several key EAU inflammatory mediators, IFN-γ, TNF-α, IL-1α, IL-4, IL-5, IL-6, IL-10, IL-17 and MCP-1 was lowered. These results suggest that COS may be a potential treatment for posterior uveitis.


Subject(s)
Chitosan/pharmacology , NF-kappa B/metabolism , Retinitis/drug therapy , Animals , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Chitosan/metabolism , Disease Models, Animal , Eye Proteins/adverse effects , Eye Proteins/metabolism , Female , Inflammation/metabolism , Interleukin-17/immunology , Lymphocyte Activation/immunology , Mice , Mice, Inbred C57BL , Oligosaccharides/therapeutic use , Retina/metabolism , Retinol-Binding Proteins/adverse effects , Retinol-Binding Proteins/metabolism , Tumor Necrosis Factor-alpha/immunology , Uveitis/drug therapy , Uveitis/metabolism
3.
J Leukoc Biol ; 107(1): 105-112, 2020 01.
Article in English | MEDLINE | ID: mdl-31729784

ABSTRACT

Bortezomib suppressing NF-κB activity is an effective therapy for patients with myeloma or lymphoma. However, this drug can cause adverse effects, neutropenia, and recurrent infections of herpes viruses. Among herpes viruses, HSV-1 can reactivate to induce mortality. The important issues regarding how bortezomib diminishes neutrophils, whether bortezomib can induce HSV-1 reactivation, and how bortezomib exacerbates HSV-1 infection, need investigation. Using the murine model, we found that bortezomib induced HSV-1 reactivation. Bortezomib diminished neutrophil numbers in organs of uninfected and HSV-1-infected mice and turned a nonlethal infection to lethal with elevated tissue viral loads. In vitro results showed that bortezomib and HSV-1 collaborated to enhance the death and apoptosis of mouse neutrophils. The leukocyte deficiency induced by chemotherapies is generally believed to be the cause for aggravating virus infections. Here we show the potential of pathogen to exacerbate chemotherapy-induced leukocyte deficiency.


Subject(s)
Antineoplastic Agents/toxicity , Bortezomib/toxicity , Herpes Simplex/etiology , Herpesvirus 1, Human/pathogenicity , Neutrophils/pathology , Viral Load , Virus Activation , Animals , Disease Models, Animal , Female , Herpes Simplex/pathology , Male , Mice , Mice, Inbred C57BL , Neutrophils/virology
4.
Acta Crystallogr D Biol Crystallogr ; 69(Pt 5): 747-55, 2013 May.
Article in English | MEDLINE | ID: mdl-23633583

ABSTRACT

The Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (M(pro)) cleaves two virion polyproteins (pp1a and pp1ab); this essential process represents an attractive target for the development of anti-SARS drugs. The functional unit of M(pro) is a homodimer and each subunit contains a His41/Cys145 catalytic dyad. Large amounts of biochemical and structural information are available on M(pro); nevertheless, the mechanism by which monomeric M(pro) is converted into a dimer during maturation still remains poorly understood. Previous studies have suggested that a C-terminal residue, Arg298, interacts with Ser123 of the other monomer in the dimer, and mutation of Arg298 results in a monomeric structure with a collapsed substrate-binding pocket. Interestingly, the R298A mutant of M(pro) shows a reversible substrate-induced dimerization that is essential for catalysis. Here, the conformational change that occurs during substrate-induced dimerization is delineated by X-ray crystallography. A dimer with a mutual orientation of the monomers that differs from that of the wild-type protease is present in the asymmetric unit. The presence of a complete substrate-binding pocket and oxyanion hole in both protomers suggests that they are both catalytically active, while the two domain IIIs show minor reorganization. This structural information offers valuable insights into the molecular mechanism associated with substrate-induced dimerization and has important implications with respect to the maturation of the enzyme.


Subject(s)
Cysteine Endopeptidases/chemistry , Severe acute respiratory syndrome-related coronavirus/enzymology , Viral Matrix Proteins/chemistry , Viral Proteins/chemistry , Binding Sites , Coronavirus 3C Proteases , Coronavirus M Proteins , Crystallography, X-Ray , Cysteine Endopeptidases/genetics , Cysteine Endopeptidases/metabolism , Models, Molecular , Mutation , Protein Conformation , Protein Multimerization , Severe acute respiratory syndrome-related coronavirus/chemistry , Viral Matrix Proteins/genetics , Viral Matrix Proteins/metabolism , Viral Proteins/genetics , Viral Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL